Loading...
Header Logo
Keywords
Last Name
Institution

JONATHAN MICHAEL FLANAGAN

TitleAssistant Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pediatrics
DivisionPediatrics-Hematology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Faculty Mentor
    Collapse Verify Publications

    Collapse Overview 
    Collapse overview
    The long term goal of my research is to identify genetic variants that affect the clinical severity of patients with sickle cell anemia (SCA). SCA is a common disorder caused by a single mutation of the beta-globin gene but the individual severity of clinical outcome is highly variable. It is increasingly apparent that some of this variability is due to co-inheritance of genetic variants other than the SCA mutation. I have a comprehensive background in the study of genetics and completed my postdoctoral training in the field of hematology. This has allowed me to complete several translational projects involving genetics and hematology. During my postdoctoral fellowships at The Scripps Research Institute and St. Jude Children’s Research Hospital, I carried out research projects that investigated the molecular mechanisms of iron overload and the genetic modifiers that affected patient response to the drug hydroxyurea. My laboratory is now working on identifying novel genetic variants that are associated with disease severity of SCA and using state-of-the art molecular biology techniques to decipher the molecular pathways that are involved.

    Collapse Research 
    Collapse research activities and funding
    R21HL123641     (FLANAGAN, JONATHAN MICHAEL)Aug 1, 2015 - Jul 31, 2017
    NIH/NHLBI
    Genetic Modifiers of Transfusional Iron Overload
    Role: Principal Investigator

    R56HL136415     (FLANAGAN, JONATHAN MICHAEL)Sep 25, 2017 - Aug 31, 2018
    NIH/NHLBI
    NOVEL PATHWAYS IN ISCHEMIC STROKE IN SICKLE CELL ANEMIA
    Role: Principal Investigator

    R01HL136415     (FLANAGAN, JONATHAN MICHAEL)Aug 1, 2019 - Jun 30, 2022
    NIH/NHLBI
    Novel Pathways in Ischemic Stroke in Sickle Cell Anemia
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Mathur T, Singh KA, R Pandian NK, Tsai SH, Hein TW, Gaharwar AK, Flanagan JM, Jain A. Organ-on-chips made of blood: endothelial progenitor cells from blood reconstitute vascular thromboinflammation in vessel-chips. Lab Chip. 2019 Jul 23; 19(15):2500-2511. PMID: 31246211.
      View in: PubMed
    2. Mwesigwa S, Moulds JM, Chen A, Flanagan J, Sheehan VA, George A, Hanchard NA. Whole-exome sequencing of sickle cell disease patients with hyperhemolysis syndrome suggests a role for rare variation in disease predisposition. Transfusion. 2018 03; 58(3):726-735. PMID: 29210071.
      View in: PubMed
    3. Chou ST, Flanagan JM, Vege S, Luban NLC, Brown RC, Ware RE, Westhoff CM. Whole-exome sequencing for RH genotyping and alloimmunization risk in children with sickle cell anemia. Blood Adv. 2017 Aug 08; 1(18):1414-1422. PMID: 29296782.
      View in: PubMed
    4. Friedrisch JR, Sheehan V, Flanagan JM, Baldan A, Summarell CC, Bittar CM, Friedrisch BK, Wilke II, Ribeiro CB, Daudt LE, da Rocha Silla LM. The role of BCL11A and HMIP-2 polymorphisms on endogenous and hydroxyurea induced levels of fetal hemoglobin in sickle cell anemia patients from southern Brazil. Blood Cells Mol Dis. 2016 11; 62:32-37. PMID: 27838552.
      View in: PubMed
    5. Schaefer BA, Flanagan JM, Alvarez OA, Nelson SC, Aygun B, Nottage KA, George A, Roberts CW, Piccone CM, Howard TA, Davis BR, Ware RE. Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia. PLoS One. 2016; 11(10):e0164364. PMID: 27711207.
      View in: PubMed
    6. Sheehan VA, Crosby JR, Sabo A, Mortier NA, Howard TA, Muzny DM, Dugan-Perez S, Aygun B, Nottage KA, Boerwinkle E, Gibbs RA, Ware RE, Flanagan JM. Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia. PLoS One. 2014; 9(10):e110740. PMID: 25360671.
      View in: PubMed
    7. Sheehan VA, Luo Z, Flanagan JM, Howard TA, Thompson BW, Wang WC, Kutlar A, Ware RE. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. Am J Hematol. 2013 Jul; 88(7):571-6. PMID: 23606168.
      View in: PubMed
    8. Flanagan JM, Sheehan V, Linder H, Howard TA, Wang YD, Hoppe CC, Aygun B, Adams RJ, Neale GA, Ware RE. Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia. Blood. 2013 Apr 18; 121(16):3237-45. PMID: 23422753.
      View in: PubMed
    9. Flanagan JM, Steward S, Howard TA, Mortier NA, Kimble AC, Aygun B, Hankins JS, Neale GA, Ware RE. Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia. Br J Haematol. 2012 Apr; 157(2):240-8. PMID: 22360576.
      View in: PubMed
    10. McGann PT, Flanagan JM, Howard TA, Dertinger SD, He J, Kulharya AS, Thompson BW, Ware RE. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatr Blood Cancer. 2012 Aug; 59(2):254-7. PMID: 22012708.
      View in: PubMed
    11. Ware RE, Despotovic JM, Mortier NA, Flanagan JM, He J, Smeltzer MP, Kimble AC, Aygun B, Wu S, Howard T, Sparreboom A. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011 Nov 03; 118(18):4985-91. PMID: 21876119.
      View in: PubMed
    12. McGann PT, Howard TA, Flanagan JM, Lahti JM, Ware RE. Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure. Br J Haematol. 2011 Jul; 154(1):134-40. PMID: 21542824.
      View in: PubMed
    13. Flanagan JM, Frohlich DM, Howard TA, Schultz WH, Driscoll C, Nagasubramanian R, Mortier NA, Kimble AC, Aygun B, Adams RJ, Helms RW, Ware RE. Genetic predictors for stroke in children with sickle cell anemia. Blood. 2011 Jun 16; 117(24):6681-4. PMID: 21515823.
      View in: PubMed
    14. Flanagan JM, Howard TA, Mortier N, Avlasevich SL, Smeltzer MP, Wu S, Dertinger SD, Ware RE. Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res. 2010 Apr 30; 698(1-2):38-42. PMID: 20230905.
      View in: PubMed
    15. Bouchier-Hayes L, Oberst A, McStay GP, Connell S, Tait SW, Dillon CP, Flanagan JM, Beere HM, Green DR. Characterization of cytoplasmic caspase-2 activation by induced proximity. Mol Cell. 2009 Sep 24; 35(6):830-40. PMID: 19782032.
      View in: PubMed
    16. Flanagan JM, Steward S, Hankins JS, Howard TM, Neale G, Ware RE. Microarray analysis of liver gene expression in iron overloaded patients with sickle cell anemia and beta-thalassemia. Am J Hematol. 2009 Jun; 84(6):328-34. PMID: 19384939.
      View in: PubMed
    17. Flanagan JM, Truksa J, Peng H, Lee P, Beutler E. In vivo imaging of hepcidin promoter stimulation by iron and inflammation. Blood Cells Mol Dis. 2007 May-Jun; 38(3):253-7. PMID: 17331760.
      View in: PubMed
    18. Flanagan JM, Peng H, Beutler E. Effects of alcohol consumption on iron metabolism in mice with hemochromatosis mutations. Alcohol Clin Exp Res. 2007 Jan; 31(1):138-43. PMID: 17207112.
      View in: PubMed
    19. Flanagan JM, Gerber AL, Cadet JL, Beutler E, Sipe JC. The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum Genet. 2006 Nov; 120(4):581-8. PMID: 16972078.
      View in: PubMed
    20. Flanagan JM, Rhodes M, Wilson M, Beutler E. The identification of a recurrent phosphoglycerate kinase mutation associated with chronic haemolytic anaemia and neurological dysfunction in a family from USA. Br J Haematol. 2006 Jul; 134(2):233-7. PMID: 16740138.
      View in: PubMed
    21. Flanagan JM, Beutler E. The genetic basis of human erythrocyte pyridoxal kinase activity variation. Haematologica. 2006 Jun; 91(6):801-4. PMID: 16704963.
      View in: PubMed
    22. Noel N, Flanagan JM, Flanagan J, Ramirez Bajo MJ, Kalko SG, Mañú Mdel M, Garcia Fuster JL, Perez de la Ossa P, Carreras J, Beutler E, Vives Corrons JL. Two new phosphoglycerate kinase mutations associated with chronic haemolytic anaemia and neurological dysfunction in two patients from Spain. Br J Haematol. 2006 Feb; 132(4):523-9. PMID: 16412025.
      View in: PubMed
    23. Flanagan JM, Peng H, Wang L, Gelbart T, Lee P, Johnson Sasu B, Beutler E. Soluble transferrin receptor-1 levels in mice do not affect iron absorption. Acta Haematol. 2006; 116(4):249-54. PMID: 17119325.
      View in: PubMed
    24. Tighe O, Flanagan JM, Kernan F, O'Neill C, Naughten E, Mayne PD, Croke DT. Frequency distribution of the Los Angeles and Duarte galactose-1-phosphate uridyltransferase variant alleles in the Irish population. Mol Genet Metab. 2004 Aug; 82(4):345-7. PMID: 15308134.
      View in: PubMed
    25. Flanagan JM, Tighe O, O' Neill C, Naughten E, Mayne PD, Croke DT. Identification of sequence variation in the galactose-1-phosphate uridyl transferase gene by dHPLC. Mol Genet Metab. 2004 Feb; 81(2):133-6. PMID: 14741195.
      View in: PubMed
    FLANAGAN's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description